Repligen Corporation (RGEN) — Fair Value Analysis

Base-case fair value (P50): $130.27 · Current price: $163.90 · Verdict: Overvalued

The Verdict on RGEN

REPLIGEN CORP (RGEN) is currently assessed as Fairly Valued based on our latest Monte Carlo simulations. Our analysis indicates a median fair value (P50) of $130.27 for RGEN, suggesting a -20.5% difference compared to its current trading price of $163.90. While this median points to potential downside from today's level, the comprehensive distribution of thousands of forward scenarios consistently places RGEN within its statistically fair value range. This "Fairly Valued" verdict reflects that, despite trading above its median fair value, $163.90 remains within the wider expected probabilistic outcomes for RGEN.

How RGEN stacks up against peers

RGEN's operational and financial health is categorized as an average quality tier relative to its sector. This average quality tier directly informs the parameters of our Monte Carlo model, influencing the range and volatility of potential future outcomes for its fair value. A stock with average quality might exhibit a broader fair value distribution compared to a premium-tiered company, suggesting a wider plausible range of outcomes around its $130.27 estimate. The current price of $163.90 relative to the average quality tier implies investors are pricing RGEN consistently with its observed fundamentals and sector standing, supporting the Fairly Valued assessment despite the implied -20.5% from the median.

What this means for investors

For investors, the Fairly Valued verdict on RGEN, despite a -20.5% from the $130.27, suggests that the stock currently sits within a reasonable range given its average quality tier and future potential. While a downside scenario from the current $163.90 to the $130.27 is implied, our full simulation set also accounts for potential bull case outcomes that justify the current valuation. Understanding the full spectrum of RGEN's fair value distribution, including specific bear and bull case targets, is crucial for informed decision-making. Sign up for FairCurve today to explore the complete probability distribution and track RGEN's fair value as new fundamentals are released.